Octave Biosciences, a Menlo Park, CA-based commercial stage precision-medicine company, closed a $30M extension to its Series B funding.
Backers included new investors Novartis (dRx Capital); Hikma Pharmaceuticals’ venture capital arm, Hikma Ventures; and Intermountain Ventures, as well as existing investors The Blue Venture Fund, Echo Health Ventures, Section 32, Northpond Ventures, Deerfield Management, Casdin Capital, and Merck Global Health Innovation Fund.
The company intends to use the funds to accelerate its commercialization efforts to bring its multimodal solution to more multiple sclerosis patients.
Led by CEO and Founder William Hagstrom, Octave Bioscience is a commercial stage precision-medicine company delivering a care for multiple sclerosis and other neurodegenerative diseases. Its precision care solution is a set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis (MS). Octave’s platform includes a multivariate blood test to measure MS Disease Activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS nurse practitioners in real time.
Octave is currently collaborating with clinics, payers, and pharma companies across the country.
FinSMEs
26/07/2023